Palo Alto Investors LP Biomarin Pharmaceutical Inc Transaction History

Palo Alto Investors LP

$727 Million
Q3 2024

A detailed history of Palo Alto Investors LP transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Palo Alto Investors LP holds 1,090,056 shares of BMRN stock, worth $70 Million. This represents 10.54% of its overall portfolio holdings.

Number of Shares

1,090,056

Previous 1,130,167 3.55%

Holding current value

$70 Million

Previous $93 Million 17.65%

% of portfolio

10.54%

Previous 11.78%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$69.02 - $93.84 $2.77 Million - $3.76 Million	-40,111 Reduced 3.55%	1,090,056 $76.6 Million
Q2 2024 Aug 14, 2024	SELL	$74.43 - $92.22 $327,640 - $405,952	-4,402 Reduced 0.39%	1,130,167 $93 Million
Q1 2024 May 15, 2024	SELL	$83.81 - $99.0 $30.7 Million - $36.3 Million	-366,180 Reduced 24.4%	1,134,569 $99.1 Million
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $25.2 Million - $32.5 Million	-330,286 Reduced 18.04%	1,500,749 $145 Million
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $4.81 Million - $6.42 Million	-54,776 Reduced 2.9%	1,831,035 $178 Million
Q4 2022 Feb 14, 2023	SELL	$80.93 - $108.63 $7.32 Million - $9.83 Million	-90,454 Reduced 4.58%	1,885,811 $195 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $6.99 Million - $8.25 Million	-85,108 Reduced 4.13%	1,976,265 $168 Million
Q2 2022 Aug 15, 2022	SELL	$71.48 - $86.85 $5.59 Million - $6.8 Million	-78,241 Reduced 3.66%	2,061,373 $171 Million
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $5.45 Million - $6.8 Million	-73,336 Reduced 3.31%	2,139,614 $165 Million
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $543,672 - $610,488	7,200 Added 0.33%	2,212,950 $185 Million
Q1 2021 May 17, 2021	BUY	$74.73 - $90.69 $3.79 Million - $4.6 Million	50,700 Added 2.35%	2,205,750 $167 Million
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $30.7 Million - $38.1 Million	422,500 Added 24.39%	2,155,050 $189 Million
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $23.5 Million - $42.8 Million	326,600 Added 23.23%	1,732,550 $132 Million
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $11 Million - $17.2 Million	-138,213 Reduced 8.95%	1,405,950 $173 Million
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $34 Million - $46.2 Million	-476,973 Reduced 23.6%	1,544,163 $130 Million
Q4 2019 Feb 14, 2020	SELL	$64.27 - $86.37 $12.1 Million - $16.3 Million	-188,368 Reduced 8.53%	2,021,136 $171 Million
Q3 2019 Nov 14, 2019	SELL	$67.4 - $85.11 $26.8 Million - $33.8 Million	-396,981 Reduced 15.23%	2,209,504 $149 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $2.81 Million - $3.29 Million	-35,000 Reduced 1.33%	2,606,485 $223 Million
Q1 2019 May 15, 2019	BUY	$84.2 - $98.62 $6.88 Million - $8.06 Million	81,752 Added 3.19%	2,641,485 $235 Million
Q4 2018 Feb 14, 2019	BUY	$80.14 - $106.07 $825,602 - $1.09 Million	10,302 Added 0.4%	2,559,733 $218 Million
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $300,163 - $391,069	3,949 Added 0.16%	2,549,431 $240 Million
Q1 2018 May 15, 2018	BUY	$77.67 - $92.63 $3.7 Million - $4.42 Million	47,676 Added 1.91%	2,545,482 $206 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $4.79 Million - $5.64 Million	59,287 Added 2.43%	2,497,806 $223 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $197 Million - $232 Million	2,438,519	2,438,519 $227 Million

Others Institutions Holding BMRN

# of Institutions

636

Shares Held

178M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.9B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Palo Alto Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Palo Alto Investors LP with notifications on news.

Account

Palo Alto Investors LP Biomarin Pharmaceutical Inc Transaction History